Taking a BiTE out of cancer.

Q3 Nursing

Nursing Pub Date : 2025-04-01 Epub Date: 2025-03-24 DOI:10.1097/NSG.0000000000000172

Kimberly D Malkowski

引用次数: 0

Abstract

Abstract: Tarlatamab (tarlatamab-dlle) is the first bispecific T-cell engager (BiTE) therapy approved for treating a solid tumor, specifically small cell lung cancer, making it the first of its kind. It targets delta-like ligand 3 antigens on the surface of tumor cells while activating the patient's T cells. This article discusses BiTE therapy as well as its boxed warnings and precautions that nurses need to know to provide optimum patient care.

查看原文本刊更多论文

给癌症咬一口。

摘要：Tarlatamab （Tarlatamab -dlle）是首个被批准用于治疗实体肿瘤（特别是小细胞肺癌）的双特异性t细胞接触器（BiTE）疗法，是同类药物中的首个。它靶向肿瘤细胞表面的δ样配体3抗原，同时激活患者的T细胞。这篇文章讨论了咬伤治疗，以及它的黑框警告和预防措施，护士需要知道，以提供最佳的病人护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nursing Medicine-Medicine (all)

CiteScore

0.80

自引率

0.00%

发文量

338

期刊介绍： Nursing2020 (ISSN 0360-4039; online ISSN 1538-8689) published its first issue in November 1971, under founders Gene W. Jackson and Daniel Cheney. In the intervening years, its circulation has grown to over 150,000, making it one of the largest nursing journals in the world. Published monthly, Nursing2020 is widely regarded as offering current, practical contents to its readers, and has won many editorial awards testifying to the quality of its copy and graphics. The editorial and clinical staff, a 19-member Editorial Board of distinguished clinicians and practitioners, and over 100 invited reviewers help ensure the quality of this publication.